Our data suggest that evofosfamide sensitivity cannot be robustly predicted by hypoxia, MKI67, POR, or SLFN11 expression on their own, but rather is likely to be multifactorial, incorporating tumour hypoxia and other genes that influence the activation and mechanism of action of evofosfamide. The gene discussed is MKI67; the disease is neoplasm.